anti-GTPase NRas (NRAS) Antikörper

Auf finden Sie aktuell 102 GTPase NRas (NRAS) Antikörper von 17 unterschiedlichen Herstellern. Zusätzlich bieten wir Ihnen GTPase NRas Proteine (17) und GTPase NRas Kits (6) und viele weitere Produktgruppen zu diesem Protein an. Insgesamt sind aktuell 130 GTPase NRas Produkte verfügbar.
ALPS4, AV095280, fj99a10, H-RAS, HRAS, N-RAS, NRAS, NRAS1, NS6, wu:fj99a10, zgc:100761, zras-b1
Alle Antikörper anzeigen Gen GeneID UniProt
NRAS 24605 Q04970
NRAS 18176  
NRAS 4893 P01111

Meistgesuchte Reaktivitäten zu anti-GTPase NRas (NRAS) Antikörper

anti-Rat (Rattus) GTPase NRas Antikörper:

anti-Mouse (Murine) GTPase NRas Antikörper:

anti-Human GTPase NRas Antikörper:

Alle verfügbaren anti-GTPase NRas Antikörper

Sie gelangen zu unserer vorgefilterten Suche.

Weitere Antikörper gegen GTPase NRas Interaktionspartner

Mouse (Murine) GTPase NRas (NRAS) Interaktionspartner

  1. loss of one allele of Hras (zeige HRAS Antikörper) increased the sensitivity of mice to this carcinogen, and this effect was further exacerbated by the loss of the second Hras (zeige HRAS Antikörper) allele. However, loss of one or both alleles of Nras failed to alter tumor burden, either in the absence or presence of Hras (zeige HRAS Antikörper), after exposure to urethane.

  2. Genetic inactivation of Ezh2 (zeige EZH2 Antikörper) or Eed (zeige EED Antikörper) cooperates with NRASQ61K in leukemogenesis.

  3. Data indicate that S-phase kinase-associated protein 2 (SKP2) cooperates with N-Ras and AKT proto-oncogenes to promote hepatocarcinogenesis in vivo.

  4. Activated NRAS and aberrant Wnt (zeige WNT2 Antikörper) signaling conspire to drive congenital melanocytic nevus syndrome.

  5. a crucial role of RXRa (zeige RXRA Antikörper) in suppression of UVB-induced melanomas in the context of driver mutations such as activated CDK4 (zeige CDK4 Antikörper)(R24C/R24C) or oncogenic NRAS(Q61K) and altered expression of p53 (zeige TP53 Antikörper) and PTEN (zeige PTEN Antikörper)

  6. This work explains the curious predominance in human melanoma of mutations of codon 61 of NRAS over other oncogenic NRAS mutations. we show that physiologic expression of NRASQ61R, but not NRASG12D, drives melanoma formation.

  7. These data reveal the L. major-enhanced CD40-induced N-Ras activation as a novel immune evasion strategy and the potential for Ras isoform-targeted antileishmanial immunotherapy and immunoprophylaxis.

  8. NRAS expression is required for the proliferative advantage of human AML (zeige RUNX1 Antikörper) cell lines in vitro and for the maintenance of mouse Nras-mutant AML (zeige RUNX1 Antikörper) in vivo

  9. There was a nearly complete correspondence between the signaling pathways that were regulated by N-ras in immune cell types.

  10. Cbfbeta (zeige CBFB Antikörper)-SMMHC (zeige MYH11 Antikörper) and Nras(G12D) promote the survival of preleukemic myeloid progenitors primed for leukemia by activation of the MEK (zeige MDK Antikörper)/ERK (zeige EPHB2 Antikörper)/Bim (zeige BCL2L11 Antikörper) axis, and define Nras(LSL-G12D); Cbfb (zeige CBFB Antikörper)(56M) mice as a valuable genetic model for the study of AML (zeige RUNX1 Antikörper) therapies.

Human GTPase NRas (NRAS) Interaktionspartner

  1. NRAS mutations were present in 1.2% of primary papillary thyroid carcinomas, 1.3% of lymph node metastasis, and 14.3% of distant metastasis.

  2. Data suggest that isoform-specific sequences in the allosteric lobes of HRAS (zeige HRAS Antikörper), KRAS, and NRAS have an impact on biocatalysis (kinetics of GTP (zeige AK3 Antikörper) hydrolysis) and interaction with c-Raf (zeige RAF1 Antikörper) kinase, which must be due to allosteric effects on dynamics and conformational states, given the identical active sites of these isoenzymes.

  3. NRAS(Q61R) immunohistochemistry is a highly sensitive and specific tool that is useful for differentiating follicular-patterned thyroid tumors.

  4. NRAS variants were identified in 2 cases with a lethal presentation of Noonan syndrome.

  5. Mutation in NRAS gene is associated with chronic myelomonocytic leukemia.

  6. Compared with newly diagnosed multiple myeloma, an increased prevalence of mutations in the Ras pathway genes KRAS, NRAS, and/or BRAF (zeige BRAF Antikörper) (72%), as well as TP53 (zeige TP53 Antikörper) (26%), CRBN (zeige CRBN Antikörper) (12%), and CRBN (zeige CRBN Antikörper) pathway genes (10%) was observed.

  7. Our data suggest that testing for any RAS mutation is unlikely to change the clinical management of thyroid nodules that have indeterminate cytology

  8. Examination of clinical parameters of these tumors found those with APA (zeige ENPEP Antikörper) of NRAS and c-JUN (zeige JUN Antikörper) to be smaller and less proliferative

  9. Equilibrium dissociation constants were determined for the binding of HRAS, KRAS, NRAS and RRAS2 to the RAS binding (RB) domain of binding proteins.

  10. Studies indicate that RAS proteins were among the first oncogenes identified and are mutationally activated in 30% of all cancer types.

Zebrafish GTPase NRas (NRAS) Interaktionspartner

  1. Although oncogenic NRAS expression alone was found to be insufficient to promote tumor formation, loss of functional p53 (zeige TP53 Antikörper) was found to collaborate with NRAS expression in the genesis of melanoma.

GTPase NRas (NRAS) Antigen-Profil

Beschreibung des Gens

This is an N-ras oncogene encoding a membrane protein that shuttles between the Golgi apparatus and the plasma membrane. This shuttling is regulated through palmitoylation and depalmitoylation by the ZDHHC9-GOLGA7 complex. The encoded protein, which has intrinsic GTPase activity, is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase activating protein. Mutations in this gene have been associated with somatic rectal cancer, follicular thyroid cancer, autoimmune lymphoproliferative syndrome, Noonan syndrome, and juvenile myelomonocytic leukemia.

Alternative names and synonyms associated with GTPase NRas (NRAS)

  • GTPase NRas (Tsp_01117) Antikörper
  • African clawed frog N-ras (n-ras) Antikörper
  • neuroblastoma ras oncogene (Nras) Antikörper
  • neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) Antikörper
  • neuroblastoma RAS viral (v-ras) oncogene homolog (nras) Antikörper
  • ALPS4 Antikörper
  • AV095280 Antikörper
  • fj99a10 Antikörper
  • H-RAS Antikörper
  • HRAS Antikörper
  • N-RAS Antikörper
  • NRAS Antikörper
  • NRAS1 Antikörper
  • NS6 Antikörper
  • wu:fj99a10 Antikörper
  • zgc:100761 Antikörper
  • zras-b1 Antikörper

Bezeichner auf Proteinebene für anti-GTPase NRas (NRAS) Antikörper

GTPase NRas , transforming protein N-Ras , neuroblastoma RAS viral (v-ras) oncogene homolog , N-ras oncogene , p21 protein , N-ras protein part 4 , v-ras neuroblastoma RAS viral oncogene homolog , ras p21 , N-ras oncogene p21 , etID18709.8 , neuroblastoma RAS viral oncogene-like protein , neuroblastoma ras oncogene , v-Ha-ras Harvey rat sarcoma viral oncogene homolog

10905151 Trichinella spiralis
399446 Xenopus laevis
24605 Rattus norvegicus
18176 Mus musculus
100135584 Cavia porcellus
4893 Homo sapiens
403872 Canis lupus familiaris
30380 Danio rerio
419885 Gallus gallus
100739349 Sus scrofa
506322 Bos taurus
100174317 Pongo abelii
Ausgewählte Anbieter für anti-GTPase NRas (NRAS) Antikörper
Haben Sie etwas anderes gesucht?